The estimated Net Worth of Athanasios Skarpelos is at least $12.2 Million dollars as of 25 May 2022. Mr. Skarpelos owns over 50,000 units of Anavex Life Sciences stock worth over $6,958,630 and over the last 17 years he sold AVXL stock worth over $5,123,753. In addition, he makes $93,871 as Independent Director at Anavex Life Sciences.
Athanasios has made over 5 trades of the Anavex Life Sciences stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of AVXL stock worth $46,000 on 25 May 2022.
The largest trade he's ever made was selling 950,000 units of Anavex Life Sciences stock on 26 October 2007 worth over $1,615,000. On average, Athanasios trades about 180,261 units every 338 days since 2007. As of 25 May 2022 he still owns at least 1,356,458 units of Anavex Life Sciences stock.
You can see the complete history of Mr. Skarpelos stock trades at the bottom of the page.
Athanasios Skarpelos serves as Independent Director of the Company. He is a self-employed investor with 20 years of experience working with private and public companies. For more than 12 years, he has been focused on biotechnology companies involved in drug discovery and drug development projects. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex.
As the Independent Director of Anavex Life Sciences, the total compensation of Athanasios Skarpelos at Anavex Life Sciences is $93,871. There are 5 executives at Anavex Life Sciences getting paid more, with Christopher Missling having the highest compensation of $3,380,040.
Athanasios Skarpelos is 53, he's been the Independent Director of Anavex Life Sciences since 2013. There are 5 older and 4 younger executives at Anavex Life Sciences. The oldest executive at Anavex Life Sciences Corporation is Stephan Toutain, 55, who is the Chief Operating Officer.
Athanasios's mailing address filed with the SEC is 630 5TH AVENUE 20TH FLOOR, , NEW YORK, NY, 10111.
Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling und Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Anavex Life Sciences executives and other stock owners filed with the SEC include: